Financial Performance - The company's operating revenue for Q1 2023 was CNY 1.688 billion, a decrease of 9.35% year-on-year[4] - Net profit attributable to shareholders was CNY 122.41 million, an increase of 39.78% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 126.33 million, up 32.10% year-on-year[4] - The core brand operation business achieved revenue of CNY 917 million, a growth of 10.97% year-on-year[7] - The wholesale and distribution business reported revenue of CNY 677 million, a decline of 27.56% year-on-year[7] - The retail business generated revenue of CNY 86 million, down 8.57% year-on-year[7] - Total operating revenue for Q1 2023 was CNY 1,686,422,354.66, a decrease of 9.3% compared to CNY 1,860,324,319.90 in the same period last year[17] - Net profit for Q1 2023 was CNY 119,549,046.03, representing an increase of 38.7% from CNY 86,167,957.38 in Q1 2022[18] - Earnings per share (EPS) for Q1 2023 was CNY 0.2331, up from CNY 0.1668 in the previous year[19] Cash Flow and Assets - The net cash flow from operating activities was CNY 154.35 million, a significant increase of 219.87% year-on-year[4] - Cash flow from operating activities increased to CNY 1,934,367,869.47, compared to CNY 1,798,294,219.38 in the same period last year[20] - The net cash flow from operating activities for Q1 2023 was ¥154,352,220.05, compared to a negative cash flow of ¥128,761,948.04 in Q1 2022, indicating a significant improvement[21] - Total cash outflow from operating activities was ¥1,780,015,649.42, down from ¥1,927,056,167.42 in the same period last year[21] - The ending balance of cash and cash equivalents was ¥880,720,784.89, down from ¥1,069,897,263.74 at the end of Q1 2022[21] - The company's cash and cash equivalents reached CNY 1,145,973,401.21, up from CNY 1,047,765,015.27 at the beginning of the year, reflecting a growth of approximately 9.36%[14] - Accounts receivable decreased to CNY 1,844,001,727.03 from CNY 2,028,157,194.77, indicating a reduction of about 9.08%[14] - Inventory increased to CNY 734,246,491.68 from CNY 650,098,447.97, representing an increase of approximately 12.93%[15] Liabilities and Equity - The total current liabilities as of March 31, 2023, were CNY 2,538,325,243.19, a decrease from CNY 2,603,806,929.80 at the beginning of the year[15] - The company's total liabilities decreased to CNY 2,686,288,884.74 from CNY 2,750,922,581.18 year-on-year[18] - The total equity attributable to shareholders of the parent company increased to CNY 2,424,162,640.52, up from CNY 2,301,713,910.75 in the previous year[18] - The equity attributable to shareholders was CNY 2.424 billion, reflecting a growth of 5.32% year-on-year[4] Shareholder Information - The company had a total of 9,834 common shareholders at the end of the reporting period[8] - The top ten shareholders did not participate in margin trading or securities lending activities[12] Investments and Expenses - Research and development expenses for Q1 2023 were CNY 3,055,723.40, indicating ongoing investment in innovation[18] - The company reported a decrease in sales expenses to CNY 246,820,599.16 from CNY 286,178,225.72 year-on-year, reflecting cost control measures[18] - The company's long-term equity investments stood at CNY 181,024,756.70, slightly down from CNY 181,566,656.38[15] Regulatory and Agreements - The company signed a promotion agreement with Novartis Pharma Co., Ltd. in February 2023 to expand marketing activities for a designated product[13] - The company received approval from the China Securities Regulatory Commission for the issuance of convertible bonds on March 28, 2023[13] Other Financial Information - Other comprehensive income after tax was CNY -907,050.85, compared to CNY 38,308.91 in the previous year, indicating fluctuations in financial assets[19] - The report for Q1 2023 was not audited[22]
百洋医药(301015) - 2023 Q1 - 季度财报